#USA #Chicago #Seegene #CURECA™ #STAgora

Seegene Unveils Groundbreaking Technologies at ADLM 2025

Seegene Inc., a powerhouse in molecular diagnostics, recently unveiled two groundbreaking technologies, CURECA™ and STAgora™, at the ADLM 2025 conference held in Chicago from July 29 to 31. These advancements are set to redefine the landscape of diagnostic testing, paving the way for enhanced laboratory automation and real-time data analysis, crucial for efficient infectious disease management.

Commitments to Innovation in Diagnostics

During a press conference, Dr. Jong-Yoon Chun, Seegene's CEO, emphasized the importance of these technologies in realizing a future equipped with robust diagnostic solutions. "With CURECA™ and STAgora™, we are taking significant strides towards revolutionizing diagnostics," he declared. These innovations aim not only to streamline complex testing procedures but also to maximize the effectiveness of diagnostic data, aligning with Seegene's mission of contributing to a world free from disease.

CURECA™: A Leap in Automation

CURECA™ represents a monumental step forward in PCR testing, being the first fully unattended automated PCR system in the industry. Designed to eliminate the dependency on highly trained personnel and manual processes, CURECA™ ensures a continuous 24/7 operation for laboratories. Its core component, CURECA™ Prep, processes various sample types, including urine, blood, and sputum, all while adhering to strict automation standards. This module addresses one of the biggest challenges in lab automation — handling diverse biological specimens.

The system encompasses all steps of PCR testing, from sample loading and nucleic acid extraction to amplification and analysis, without any manual intervention. By minimizing human errors and enhancing workflow efficiency, CURECA™ empowers laboratory staff to concentrate on more complex tasks, thereby optimizing overall productivity.

STAgora™: Transforming Data into Insights

The second innovation, STAgora™, is a real-time data analytics platform that interprets PCR test data. It offers laboratories a comprehensive view of diagnostic workflows, allowing for the monitoring of infection trends, positivity rates, and co-infection patterns through over 40 analytical tools. Unlike conventional databases that provide limited insights, STAgora™ aggregates and anonymizes data, making it accessible for inter-facility comparisons and fostering quicker identification of infection patterns.

This platform aims to empower healthcare institutions by facilitating data-driven decision-making, crucial for timely responses to emerging health threats. As Dr. Chun mentioned, STAgora™ is essential for creating extensive statistical datasets and enhancing collaborative efforts across different institutions.

Striving for a Disease-Free Future

Dr. Chun reiterated Seegene's long-term vision of eradicating diseases through technological innovation. The introduction of CURECA™ and STAgora™ completes the company's five core technological pillars, which include proprietary PCR technology, an automated assay development system, a global technology-sharing initiative, fully automated PCR tests, and real-time data analytics. This holistic approach is designed to enhance diagnostic capabilities while supporting global health initiatives.

The technological advancements presented at ADLM 2025 sparked significant interest among industry experts, with Jamel Giuma, President of JTG Consulting Group, praising CURECA™ as one of the most innovative solutions observed in recent years. He expressed confidence that it could simplify laboratory workflows and drastically improve operational efficiency.

Conclusion

In summary, Seegene's CURECA™ and STAgora™ not only address long-standing challenges in molecular diagnostics but also signify a transformative shift in how laboratories operate. Much like smartphones have reshaped communication and electric vehicles have altered transportation, these technologies promise to redefine diagnostic capabilities worldwide—a vital step towards achieving Seegene's vision of a world without diseases.

Disclaimer: CURECA™ and STAgora™ as introduced are pre-commercial technologies currently in development and are not available for clinical diagnostics in any jurisdiction.